Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 3, 2000, Pages 294-299

  Shima, Toshihide ^a   Tada, Hisashi ^b   Morimoto, Michio ^b   Nakagawa, Yoshihiro ^b   Obata, Hirozumi ^a   Sasaki, Toshiyuki ^a   Park, Hyohun ^a   Nakajo, Shinobu ^a   Nakashima, Toshiaki ^c   Okanoue, Takeshi ^c   Kashima, Kei ^c  

^a Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^b HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Histological activity index score; Interferon; Liver function test; Liver histology; Serum total bile acid; Sustained responder

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BILE ACID; CHOLESTEROL; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BILE ACID BLOOD LEVEL; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER FUNCTION TEST; LIVER HISTOLOGY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

EID: 6744224441     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02126.x     Document Type: Article

References (23)

1. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N. Engl. J. Med. 1986; 315: 1575-8.
2. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
3. DiBisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
4. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1326-9.
5. Yoshioka K, Higashi Y, Yamada M et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 1995; 15: 57-62.
6. 2b. Hepatology 1993; 18: 1300-5.
7. Guechot J, Loria A, Serfaty L et al. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: Effect of α-interferon therapy. J. Hepatol. 1995; 22: 22-6.
8. Paumgartner G, Mannes GA, Stellaard F. Serum bile acids and bile acid tolerance tests in liver disease. In: Barbara L, Dowling RH, Hofmann AF, Roda E, eds. Bile Acids in Gastroenterology. Lancaster: MTP Press Limited. 1983; 217-22.
9. Paumgartner G. Serum bile acids. Physiological determinants and results in liver disease. J. Hepatol. 1986; 2: 291-8.
10. Reichel C, Sauerbruch T. Serum bile acids: Physiology and clinical relevance. Eur. J. Gastroenterol. Hepatol. 1995; 7: 951-3.
11. Festi D, Labate AMM, Roda A et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983; 3: 707-13.
12. Monroe PS, Baker AL, Schneider JF et al. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 2: 317-22.
13. Kishimoto Y, Hijiya S, Takeda I. Clinical significance of fasting serum bile acid in the long-term observation of chronic liver disease. Am. J. Gastroenterol. 1985; 80: 136-8.
14. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
15. Kakumu S, Aiyama T, Okumura A et al. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J. Gastroenterol. Hepatol. 1997; 12: 468-72.
16. Mashige F, Imai K, Osuga T. A simple and sensitive assay of total serum bile acid. Clin. Chim. Acta 1976; 70: 79-86.
17. Desmet VJ, Gerber M, Hoofnagle JH et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
18. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
19. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115-50.
20. Lopez Morante AJ, Saez-Royuela F, Casanova Valero F et al. Immune thrombocytopenia after α-interferon therapy in a patient with chronic hepatitis C. Am. J. Gastroenterol. 1992; 87: 809-10.
21. Kaplan MM. Laboratory tests. In: Schiff L, Schiff ER, eds. Diseases of the Liver. Philadelphia: JB Lippincott. 1987; 219-60.
22. Murphy GM. Serum bile acids. In: Setchell KDR, Kritchevsky D, Nair PP, eds. The Bile Acids: Chemistry, Physiology, and Metabolism. New York: Plenum Press. 1988; 379-403.
23. Ferraris R, Colombatti G, Fiorentini MT et al. Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity and predictive value. Dig. Dis. Sci. 1983; 28: 129-36.